BioNotebook: Spring heats up the IPO market
This article was originally published in Scrip
You may also be interested in...
Private Company Edition: Life science firms in J&J's JLabs incubators have raised $9.4bn to date from deals and financings, including five IPOs. Also, October brings a wide range of new equity and VC financings.
Emerging Company Profile: Agenovir has a unique gene-editing niche – using CRISPR/Cas9 to destroy DNA in latent viral reservoirs as opposed to other companies that snip and repair errors in the genome.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.